CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
https://doi.org/10.15690/vsp.v13i6.1195
Abstract
The article describes international multicenter controlled studies of efficacy and safety of monoclonal antibodies towards interleukin 1β — kanakinumab — when treating cryopyrin-associated periodic syndrome and systemic juvenile idiopathic arthritis in children. The results of the studies show that the remission of the disease occurred in 90% of patients with cryopyrin-associated periodic syndrome and in 40% of patients with systemic juvenile idiopathic arthritis. The safety profile was comparable to that of other biological agents.
About the Authors
Ye. I. Alekseeva
Scientific Centre of Children Health, Moscow;
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
References
1. (Вопросы современной педиатрии. 2014; 13 (6): 9–14)
2. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood. 1996; 87: 2095–2147.
3. Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitamin Horm. 2006; 74: 371–403.
4. Dinarello C. A. Interleukin-1b and the Autoinflammatory Diseases. New Engl. J. Med. 2009; 360: 2467–2470.
5. Simon A., van der Meer J. W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 292: 86–98.
6. Feldmann J., Prieur A. M., Quartier P. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 2002; 71 (1): 198–203.
7. Hassink S. G., Goldsmith D. P. Neonatal onset multisystem inflammatory disease. Arthritis Rheum. 1983; 26 (5): 668–673.
8. Hawkins P. N., Lachmann H. J., Aganna E., McDermott M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004; 50 (2): 607–612
9. Lachmann H. J., Lowe P., Felix S. D. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 2009; 206 (5): 1029–1036.
10. Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl J. Med. 2009; 360 (23): 2416–2425.
11. Aksentijevich I., Nowak M., Mallah M. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrinassociated autoinflammatory diseases. Arthritis Rheum. 2002; 46 (12): 3340–3348.
12. Petty R. E., Southwood T. R., Manners P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J. Rheumatol. 2004; 31 (2): 390–392.
13. Алексеева Е. И., Шахбазян И. Е., Исаева К.Б., Афонина Е. Ю., Бзарова Т.М. Влияние особенностей течения заболевания и глюкокортикостероидной терапии на рост детей, страдающих ювенильным ревматоидным артритом. Российский педиатрический журнал. 2003; 1: 9–14.
14. Sen E. S., Ramanan A. V. New age of biological therapies in paediatric rheumatology. Arch. Dis. Child. 2014; 99 (7): 679–685.
15. Алексеева Е. И., Алексеева А. М., Валиева С. И., Бзарова Т. М., Денисова Р. В. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 2: 42–54.
16. Frosch M., Ahlmann M., Vogl T. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (3): 883–891.
17. Holzinger D., Frosch M., Kastrup A., Prince F. H., Otten M. H., Van Suijlekom-Smit L. W. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 2012; 71 (6): 974–980.
18. Frosch M., Vogl T., Seeliger S. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003; 48 (9): 2622–2626.
19. Gattorno M., Piccini A., Lasiglie D. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58 (5): 1505–1515.
20. de Jager W., Hoppenreijs E. P., Wulffraat N. M. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 2007; 66 (5): 589–598.
21. de Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J. Rheumatol. 1998; 25 (2): 203–207.
22. Ogilvie E. M., Khan A., Hubank M. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56 (6): 1954–1965.
Review
For citations:
Alekseeva Ye.I., Denisova R.V. CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN. Current Pediatrics. 2014;13(6):9-14. (In Russ.) https://doi.org/10.15690/vsp.v13i6.1195
Views:
1192
Email this article 
